Detection of IKZF1 Deletion Mutation in Patients With Acute Lymphoblastic Leukemia and Its Impact in Therapy

NCT ID: NCT03889951

Last Updated: 2019-03-26

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 50 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2019-04-30
• Study Completion Date: 2020-05-31

Brief Summary

1. To detect IKZF-1 deletion mutations in patients with ALL.

2. To study the impact of IKZF-1 deletion mutation on therapy of ALL.

3. To study the correlation between IKZF-1 deletion mutations and BCR-ABL.

Detailed Description

Acute lymphoblastic leukemia (ALL) a malignant transformation and proliferation of lymphoid progenitor cells in the bone marrow, blood and extramedullary sites. While 80% of ALL occurs in children, it represents a devastating disease when it occurs in adults . predisposing factors include exposure to ionizing radiation, pesticides, certain solvents or viruses such as Epstein-Barr Virus and Human Immunodeficiency Virus. However, in the majority of cases, it appears as a de novo malignancy in previously healthy individuals. Chromosomal aberrations are the hallmark of ALL, but are not sufficient to generate leukemia. Characteristic translocations include t(12;21) [ETV6-RUNX1], t(1;19) [TCF3-PBX1], t(9;22) [BCR-ABL1] . More recently, a variant with a similar gene expression profile to (Philadelphia) Ph-positive ALL but without the BCR-ABL1 rearrangement has been identified. In more than 80% of cases of this so-called Ph-like ALL, the variant possesses deletions in key transcription factors involved in B-cell development including IKAROS family zinc finger 1 (IKZF1) . IKZF1 codes Ikaros, which is a member of a family of zinc- finger nuclear proteins that is required for the earliest stages of lymphoid lineage commitment and acts as tumor suppressor. Most IKZF1 mutations (94%) are deletion mutations, and there are rare point mutations resulting in loss of function of Ikaros .

There are two major deletions occur in the IKZF1 gene:

• The first one was characterized by loss of exons 4 to 7 ( 4-7) with breakpoints occurring in introns 3 and 7 on chromosome 7p12.
• The second deletion involved exons 2 to 7 ( 2-7) with a variable pattern of breakpoints in intron 1 and intron 7 in the same region as those of the 4-7 deletion.

IKZF1 mutations in cases of B-ALL are associated with poor prognosis and high risk of relapse. IKZF1 mutations are found in approximately 15% to 20% of pediatric B-ALL cases and in >75% of pediatric BCR-ABL positive ALL cases. The incidences of IKZF1 mutations in adults are approximately 50% in B-ALL cases and approximately 65% in BCR-ABL positive ALL cases .

The presence of either IKZF1 mutation or BCR- ABL has been reported to be an independent risk factor of poor prognosis for patients with B-ALL .

Conditions

ALL, Childhood

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

group 1

group of ALL patients with IKZF1 deletion mutation.

No interventions assigned to this group

group 2

group of ALL patients with no detected mutation

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

• Patients with acute lymphoblastic leukemia.

Exclusion Criteria

• patients with any other hematological malignancies.
• patients receiving chemotherapy.

• Minimum Eligible Age: 1 Year
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Assiut University

OTHER

Sponsor Role: lead

Responsible Party

Yasmin Tarek Elgammal

principal investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Central Contacts

yasmin elgammal, Mac

Role: CONTACT

yasminelgammal@hotmail.com

01015688222

alaa abdelkader, MD

Role: CONTACT

dr_alaa57@yahoo.com

Other Identifiers

ikzf1 in all

Identifier Type: -

Identifier Source: org_study_id